three TGF-J3 isoforms in gbomeruli and the tubulointerstitium. While glomerular and tubulointerstitial deposition of two matrix components induced by TGF-f3, fibronectin EDA+ and PAl-i, was significantly elevated in all diseases with matrix accumulation, correlation analysis revealed a close relationship primarily with TGF-/31. We conclude that, for a spectrum of human glomerular disorders, increased protein expression of all three TGF-/3 isoforms and proteins induced by TGF-/3 is associated with pathological accumulation of extracellular matrix.
Although progressive renal diseases such as chronic glomerulonephritis and diabetic nephropathy have different etiologies, the histological changes in the kidney are characterized ultimately by glomerulosclerosis and tubular atrophy with interstitial fibrosis resulting from excessive accumulation of extracellular matrix.
These similar pathological features suggest that a common pathogenic factor for scarring may be operating [1] [2] [3] . Recent work supports the hypothesis that overexpression of transforming growth factor-/3 (TGF-/3) is this common pathogenic factor. The original observation in the anti-thymocyte model of acute mesangioproliferative glomerulonephritis, that TOF-/3 overproduction is the cause of fibrosis [4, 5] , has been confirmed in a number of other models of kidney disease. The evidence that TGF-13 plays a causative role in fibrotic disorders of many organs has recently been reviewed [6] and continues to increase [7] . This body of work predicts that there would be overexpression of TGF-f3 in human renal disorders characterized by pathologic accumulation of extracellular matrix. The study reported here was undertaken, in part, to test this hypothesis.
In mammals, three isoforms of TGF-f3, TGF-/31, -/32 and -/33 have been identified. They are synthesized as large preproproteins, of which the biologically active TGF-/3s reside in the carboxy-terminus. Although their amino-terminal precursor sequences are dissimilar, the carhoxy-terminal 112 amino acids of the mature TGF-f3 peptides exhibit 70 to 75% conservation of amino acid sequence and 100% conservation of the nine cystine residues [8] . The TGF-f3 isoforms possess qualitatively similar actions on cells in vifro [9] , but their spatial and temporal expression differs in embryogenesis , regenerating tissues [13] [14] [15] and in fibrotic disorders [6, 7] .
It is known that in diseased glomeruli, TGF-f3 facilitates matrix accumulation in at least three ways by inducing (1) increased synthesis of matrix proteins [16, 17] , (2) increased synthesis of integrins involved in matrix assembly at the cell surface [18] , and (3) increased synthesis and matrix deposition of protease inhibitors, thereby decreasing matrix degradation [19, 20] . Neutralization of TGF-j3 activity by injection of either antibodies or the proteoglycan decorin ameliorates the effect of this growth factor [21, 22] . Across a spectrum of human renal disorders, we have examined extraeellular deposition of fibronectin EDA+ and plasminogen activator inhibitor-i (PAT-i), components which are induced by TGF-/3 and are part of two of these processes. Fibronectin EDA+, an isoform containing a spliced mRNA variant termed extra domain A, is found in healing wounds where it may act to facilitate matrix assembly, and is a sensitive marker of TGF-/3's fibrogenic actions [23] [24] [25] . PAT-i is rapidly upregulated by TUE-p and is thought to decrease matrix degradation by inhibiting generation of the matrix degrading protease, plasmin [26] [27] [28] [29] .
Multiple regression analysis was adopted to study the correlation between the level of each TGF-/3 isoform and that of each matrix protein in glomeruli and the tubulointerstitium.
Needle biopsy specimens of human kidney tissue remaining after diagnostic evaluation were obtained from Cedars-Sinai Medical Center, Los Angeles, California, USA, and Hamamatsu University Hospital, Hamamatsu, Japan. The patients were diagnosed prior to our study according to standard criteria [30] . Biopsy tissue from fifty-three patients included the following distribution of disease: thin basement membrane disease (5), minimal change disease (7), IgA nephropathy (13), focal and segmental glomerulosclerosis (5), immune complex-mediated crescentic glomerulonephritis (5), focal proliferative lupus nephritis (6), diffuse proliferative lupus nephritis (7), and diabetic nephropathy (5) . Seven normal kidney samples were used as control tissues. All samples included at least five glomeruli.
Antibodies 0
Antibodies to the three isoforms of TGF-/3 were prepared by immunizing rabbits with synthetic peptides of each isoform as described elsewhere [Ii] . Peptides of amino acid residues 4 to 19 were used to raise TGF-/31 and /32 antibodies and residues 9 to 20 were used for TGF-/33. The antibodies were purified by affinity chromatography using the respective immunogen peptides. Western blot analysis demonstrated that each purified antibody reacted only with the active, but not latent, form of the appropriate TGF-/3 isoform [11] .
Mouse monoclonal antibody to human fibronectin EDA+ and human PAl-i were obtained from Accurate Chemical and Scientific Corporation (Westbury, NY, USA) [23] and American Diagnostica, Inc. (Greenwich, CT, USA), respectively. Fluorescein isothiocyanate (FITC)-conjugated donkey F(ab')2 anti-rabbit antibody and FITC-conjugated rat F(ab')2 anti-mouse IgG antibody were used as secondary antibodies (Jackson Immunoresearch, West Grove, PA, USA).
Immunohistological examination Serial cryostat sections (4 tm) were fixed in acetone, washed in 0.15 M phosphate buffered saline, pH 7.4 (PBS), incubated with the primary antibodies, washed with PBS, incubated with the appropriate FITC-conjugated secondary antibodies, washed again and mounted with cover glasses using Bartels buffered glycerol mounting medium FA (Baxter, Deerfield, IL, USA).
The intensity of glomerular staining of TGF-/31, TGF-/32, TGF-p3, fibronectin EDA+ and PAl-i was evaluated according to the following 0 to 4 scale in coded sections observed at 400x magnification: 0 = no staining; I = weak and spotty intraglomerular staining; 2 = moderate and segmental intraglomerular staining; 3 = moderately strong and segmental, or moderate but diffuse (involving more than 50%) intraglomerular staining; and 4 = strong and diffuse intraglomerular staining. The intensity of tubulointerstitial staining in cortical areas was evaluated according to the following 0 to 4 scale in the coded sections observed at 250x magnification: 0 = no staining; I = deposition that involves less than 10% of the cortical area; 2 = involving 10 to 30%; 3 = involving 30 to 50%; and 4 = involving more than 50%. All, or at least five glomeruli and twenty randomly selected cortical tubulointerstitial areas per sample were evaluated. The mean values of the glomerular and tubulointerstitial scores were calculated.
In situ hybridization In situ hybridization to examine the expression of TGF-/31, -/32 and -/33 mRNAs was performed on fifteen samples including one sample of normal kidney, three of minimal change disease, six of IgA nephropathy, two of crescentic glomerulonephritis, one of focal proliferative lupus nephritis and two of diffuse proliferative lupus nephritis.
Four-micrometer serial sections of 4% paraformaldehyde-fixed, paraffin-embedded renal tissues were placed on 3-aminopropyltriethoxysilane-coated slides. The cDNA plasmids of murine TGF-j31, pmTGF-/31-A, murine TGF-f32, pmTGF-/32 to 9A, and murine TGF-/33, pmTGF-133 to lib were kindly provided by Dr. H.L. Moses (Vanderbilt University, Nashville, TN, USA) [31, 32] .
Antisense and sense cRNA riboprobes were generated after digestion with restriction enzymes (Takara Shuzo, Otsu, Japan), HindIII and EcoRl for TGF-/31, EcoRI and XhoI for TGF-f32, and Hindill and XhoI for TGF-/33, respectively. Riboprobes were labeled with digoxigenin using the DIG RNA labeling kit (Boehringer Mannheim Biochemica, Mannheim, Germany). Sections were rehydrated, digested with 10 g/ml of proteinase K (Boehr- Hybridization was performed with 10 nglml of digoxigenin-labeled riboprobe added to each slide and incubated for 18 hours at 50°C. The slides were washed sequentially with 5 X SSC, and 2 X SSC containing 50% formamide at 50°C and treated with 20 g/ml of RNase A (Boehringer Mannheim) for 30 minutes at 37°C. Washing was then continued once with 2 x SSC and twice with 0.2 X SSC at 50°C. Slides were washed with buffer 1(0.1 M Tris-HC1 and 0.15 M NaCI, pH 7.5) and incubated with buffer 1 containing 10% normal sheep serum and 1.5% blocking reagent (Boehringer Mannheim) for 60 minutes at room temperature. The sections were incubated with alkaline phosphatase-conjugated sheep antidigoxigenin antibody (Boehringer Mannheim) diluted 1:500 in buffer 1 containing 1% normal sheep serum for 60 minutes at cellular and associated with the matrix in the glomeruli and the tubulointerstitium. Diffuse and strong intraglomerular staining of the three TGF-13 isoforms was found in diffuse proliferative lupus nephritis, crescentic glomerulonephritis (Fig. 2) and diabetic nephropathy, while segmental intraglomerular staining was observed in IgA nephropathy, focal and segmental glomerulosclerosis and focal proliferative lupus nephritis. The Bowman's capsules, crescents, and the periglomerular and tubulointerstitial lesions with interstitial mononuclear cell infiltration and matrix deposition showed remarkably strong immunostaining of the three TGF-/3 isoforms (Fig. 2) . Some tubules surrounded by interstitial mononuclear cells and the interstitial arteries with intimal thickening were also positively stained.
Deposition of fibronectin EDA + and PAl-i
In normal kidneys, trace deposits of fibronectin EDA+ and PAl-i were observed in glomeruli and the interstitium (Figs. 3 and  4) . Similar immunostaining was seen in minimal change disease and thin basement membrane disease (Fig. 3) .
In IgA nephropathy, focal and segmental glomerulosclerosis, crescentic glomerulonephritis, lupus nephritis and diabetic nephropathy, significantly increased deposition of fibronectin EDA+ and PAl-i was noted in glomeruli showing mesangial matrix accumulation, in the crescents, and in the periglomerular and tubulointerstitial lesions where mononuclear cell infiltration and increased interstitial matrix deposition were observed (Figs. 3  and 4) . isoforms was also observed in the glomerular and tubulointerstitial lesions in lupus nephritis (Figs. 5 G, H and I). The intensity of TGF-13 mRNA expression of all three isoforms in glomerular and tubulointerstitial cells was greater in diffuse proliferative lupus nephritis than in focal proliferative lupus nephritis. In crescentic glomerulonephritis, diffuse proliferative lupus nephritis and severely proliferative IgA nephropathy, remarkably strong expression of mRNA for the three isoforms was noted in crescent cells, 
Results

Immunohistological staining of TGF-/31, -132 and -133 isoforms
In normal kidneys, slight immunoreactivity for the three TGF-J3 isoforms were observed in glomeruhi and in interlobular arteries ( Figs. 1 and 2) . In glomerular diseases that do not show excessive matrix accumulation, minimal change disease and thin basement membrane disease, glomerular and tubulointerstitial immunostaming of the three TGF-p isoforms was similar to that of normal kidneys (Fig. 1 ).
In disorders with abnormal glomerular and tubulointerstitial matrix accumulation, including IgA nephropathy, focal and segmental glomerulosclerosis, crescentic glomerulonephritis, diffuse proliferative lupus nephritis and diabetic nephropathy, significant increases in the immunoreactivity of all three TGF-f3 isoforms were noted in glomeruli (P < 0.025) and tubulointerstitium (P < 0.025; Fig. 1 ). Although significant increases in isoform staining were also found in glomeruli from patients with focal proliferative lupus nephritis and IgA nephropathy (P < 0.025), lesions with similar morphological changes, the staining intensity was less than that in glomeruli from patients with diffuse proliferative lupus nephritis (P < 0.05). No significant differences were noted in tubulointerstitial staining of focal proliferative lupus nephritis (Fig. 1) .
Immunoreactivity for all three TGF-f3 isoforms was both intra- Correlation between each TGF-j3 isoform and fibronectin EDA +
and PAL]
To determine whether expression of each isoform was equally related to the markers of matrix accumulation, fibronectin EDA+ and PAl-i, multiple regression analysis was performed. The results presented in Table 1 indicate that the levels of glomerular and tubulointerstitial deposition of fibronectin EDA+ were correlated only with TGF-J31 immunostaining and PAT-i staining was correlated with that of TGF-131 and TGF-133 but not TGF-132.
Discussion
The data presented demonstrate that, as previous studies of animal models would predict, TGF-13 protein and mRNA expression are markedly increased in human glomerular disorders characterized by extracellular matrix accumulation. Moreover, the increased immunoreactivity for fibronectin EDA+ and PAl-I strongly suggests that TGF-/3 is acting to increase matrix accumulation. These results confirm and expand a previous study from this laboratory on experimental and human diabetic nephropathy [5] and work by Yoshioka et al [33] where, in human mesangioproliferative glomerulonephritis, increases in TGF-pl protein and mRNA were shown to be closely correlated to the degree of mesangial matrix expansion.
Although the effects of the three TGF-13 isoforms on matrix production are usually similar when added to cells in vitro [9] , TGF-/31 is generally considered to be the "fibrogenic" cytokine in vivo. Intravenous or intraperitoneal injection of TGF-131 leads to In a transgenic mouse model in which the TGF-f31 gene was linked to the albumin promoter so that TGF-f31 would be produced in the liver, elevated plasma levels of TGF-/31 induced glomeruloscierosis and renal failure in some lines [37] . TGF-f31 has been shown to be upregulated in virtually all experimental models of fibrotic disease and in human diseases where it has been studied [6, 7] . Thus, the evidence supporting TGF-/31 's fibrogenic actions is considerable. In general, however, these studies have not explored the roles of -132 and -/33 in fibrogenesis. Studies of TGF-/3 isoform mRNA and immunoreactivity during normal mouse development [11, 12] , immunoreactivity during repair in regenerating liver [15] , and in excisional wound repair [14, 15] have shown spatial and temporal differences in isoform expression. We have recently reported TGF-/3 isoform staining data in acute and chronic kidney transplant rejection [38] . In chronic rejection, the results of staining were similar to those reported here: significantly increased tubulointerstitial and glomerular staining for all three TGF-/3 isoforms, as well as for fibronectiri EDA+ and PAl-i [38] . Significant increases in expression of all three TGF-f3 isoforms were also seen in two models of acute, reversible fibrosis in the rat, including pulmonary fibrosis induced by bleomycin [391 and glomerulonephritis induced by anti-thymocyte serum (unpublished data).
However, in fibrotic liver disease, when expression of TGF-f31 and -f32 was examined by in situ hybridization, an elevation of TGF-/31 mRNA was seen in most cell types with the exception of hepatocytes [40] . TGF-/32 mRNA was elevated only in bile duct epithehal cells [40] . Data on human progressive systemic sclerosis suggest that, in the skin, TGF-/32 is elevated more than TGF-/31 [41] [42] [43] . Therefore, it appears that overexpression of TGF-/3 isoforms may occur in different patterns in different tissues and during acute injury compared to chronic fibrosis. Additional studies are clearly needed.
The work presented here is the first study of human chronic fibrotic diseases where both mRNA and isoform staining have been investigated. The data show a strong correlation between TGF-f31 expression and the deposition of matrix proteins, thus confirming the role of TGF-f31 in fibrotic diseases of the kidney.
Our results also demonstrate that TGF-/32 and -133 isoform production is elevated, raising the question of whether TGF-J32 and -/33 have specific roles in chronic fibrosis or whether their actions are entirely overlapping with those of TGF-p1. The use of agents such as antibodies that neutralize specific isoforms will help to answer this question.
Little is known of the mechanism of up-regulation of TGF-l3 expression and the factors or conditions that maintain its overexpression during chronic fibrosis. It is clear from work in vitro that, depending on cell type, there is autoregulation and cross-regulation of TGF-/3 isoforms [44] . The mechanism of these autoinduction loops is known only for TGF-/31 [45] .
An interesting feature of the findings reported here, as well as those found in chronic kidney transplant rejection [38] , is that despite considerable fibrosis and cell death, the viable cells within these tissues retain the ability to overexpress TGF-J3. Although fibronectin EDA+ and PAl-i mRNA levels were not measured, the increased immunoreactivity for these proteins suggest that overexpression of TGF-/31 leads to continued matrix protein synthesis and deposition and continued inhibition of matrix degradation, thus allowing fibrosis to advance. Our data are consistent with those of Peten et al [46] , who found, by rtPCR of mRNA from microdissected glomeruhi, that a2IV collagen mRNA remained many-fold elevated above normal even in glomeruli of patients with advanced glomerulosclerosis.
The data presented support the hypothesis that overexpression of TGF-f3 underlies tissue fibrosis in chronic disease, and indicate that expression of all three isoforms is increased in a manner consistent with the severity of disease. Finally, these data provide the exciting suggestion that therapeutic intervention directed toward blocking TGF-f3 may be effective even in advanced disease.
